Simultaneous administration of live, enteric-coated adenovirus types 4, 7 and 21 vaccines: safety and immunogenicity.
The safety of and the immune response to simultaneous administration of live, enteric-coated adenovirus type 4 (ADV-4), type 7 (ADV-7), and type 21 (ADV-21) vaccines were studied. Volunteers (476 men), randomly assigned to four study groups, received three vaccines (ADV-4, ADV-7, and ADV-21), two vaccines (ADV-4 and ADV-7), one vaccine (ADV-21), or no vaccine (placebo). Subjects were observed for three weeks, and no side effects due to vaccination occured. The percentages of susceptible subjects (those entering the study with a neutralizing antibody titer of less than 1:2 to each vaccine virus received) who seroconverted to ADV-4 were similar in both groups that received ADV-4 vaccine (78% of 77 subjects and 74% of 76). However, in the group that received three vaccines, only 62% of 77 subjects seroconverted to ADV-7, compared with 79% of 76 in the group that received two vaccines (P less than 0.05). Only 58% of 77 subjects in the three-vaccine group seroconverted to ADV-21, compared with 69% of 59 in the group that received one vaccine (P greater than 0.1).
D000208:Acute Disease; D000260:Adenoviruses, Human / Q000276:immunology*; D000914:Antibodies, Viral / Q000096:biosynthesis; D006760:Hospitalization; D006801:Humans; D008171:Lung Diseases / Q000517:prevention & control*; D008297:Male; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use
D000914:Antibodies, Viral; D014765:Viral Vaccines